Yourgene Health : 19 August 2021 - Yourgene’s COVID-19 testing investment reaps rewards DHSC contract secured to support COVID-19 surge testing +

Yourgene Health plc

('Yourgene' or the 'Group' or the 'Company')

Yourgene's COVID-19 testing investment reaps rewards
DHSC contract secured to support COVID-19 surge testing

Manchester, UK 19 August 2021: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, confirms that Yourgene Genomic Services ('YGS') has been awarded a contract for provision of laboratory capacity to the NHS Test and Trace Programme for COVID-19 testing by the Department of Health & Social Care (DHSC).

In April 2021, the Company announced it was successful in securing tenders under Public Health England's National Microbiology Framework for Lots 1-4 and was one of only three companies to successfully be awarded all four Lots. This meant public health authorities across the UK were able to issue call-off contracts to procure goods and testing services from Yourgene.

This contract is the first to come of the National Microbiology Framework Lot wins announced earlier this year, using Yourgene's high throughput automated COVID-19 services testing laboratory in Citylabs 1.0, Manchester. The final contract notice value is the maximum estimated value of the contract. Actual value will depend on services purchased. There is no committed spend.

Lyn Rees, Chief Executive Officer, commented:'We are delighted to have been awarded this first contract from the framework, supporting the Government's testing needs utilising our recently completed high throughput COVID-19 diagnostic testing laboratory.'

This announcement contains inside information for the purposes of the UK Market Abuse Regulation. The Directors of the Company take responsibility for this announcement.

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.

Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger^® Technology, the Yourgene LightBench^® and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.

Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker 'YGEN'. Follow us on LinkedIn and Twitter.